Isosorbide mononitrate and Tolvaptan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Isosorbide mononitrate (isosorbide mononitrate) and Tolvaptan (tolvaptan). Common drug interactions include atrial fibrillation among females and chest discomfort among males.

The phase IV clinical study analyzes what interactions people have when they take Isosorbide mononitrate and Tolvaptan. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Isosorbide mononitrate?

Isosorbide mononitrate has active ingredients of isosorbide mononitrate. It is often used in angina. eHealthMe is studying from 26,858 Isosorbide mononitrate users. Check the latest studies of Isosorbide mononitrate.

What is Tolvaptan?

Tolvaptan has active ingredients of tolvaptan. eHealthMe is studying from 5,685 Tolvaptan users. Check the latest studies of Tolvaptan.



On Jul, 12, 2026

29 people who take Isosorbide mononitrate and Tolvaptan together, and have interactions are studied.

Isosorbide mononitrate and Tolvaptan drug interactions.

What are the common drug interactions of Isosorbide Mononitrate and Tolvaptan, by gender? *:

female:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Pulmonary oedema (fluid accumulation in the lungs)
  3. Viral infection
  4. Blood sodium decreased
  5. Dehydration (dryness resulting from the removal of water)
  6. Hypotension (abnormally low blood pressure)
  7. Death
  8. Abdominal distension
  9. Cardiorenal syndrome (kidney failure and heart failure)
  10. Cough

male:

  1. Chest discomfort
  2. Vertigo
  3. Dyskinesia (abnormality or impairment of voluntary movement)
  4. Electrocardiogram qt prolonged
  5. Heat illness
  6. Nausea (feeling of having an urge to vomit)
  7. Blood glucose increased
  8. Blood triglycerides increased
  9. Cardiac failure
  10. Glomerular filtration rate decreased

What are the common drug interactions of Isosorbide Mononitrate and Tolvaptan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Dizziness
  2. Hepatitis (inflammation of the liver)
  3. Blood creatinine increased
  4. Blood glucose increased
  5. Blood triglycerides increased
  6. Glomerular filtration rate decreased
  7. Hepatic enzyme increased
  8. Hepatic steatosis (fatty liver disease)
  9. High density lipoprotein decreased
  10. Polyuria (production of too much dilute urine)

50-59:

  1. Atrioventricular block first degree (heart block first degree)
  2. Blood sodium decreased
  3. Bundle branch block left (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the left ventricle)
  4. Cardiac failure
  5. Hepatic congestion (liver congestion)
  6. Hypotension (abnormally low blood pressure)
  7. Oliguria (not enough urine)
  8. Pulmonary congestion (congestion in the lungs)
  9. Syncope (loss of consciousness with an inability to maintain postural tone)

60+:

  1. Chest discomfort
  2. Vertigo
  3. Heat illness
  4. Nausea (feeling of having an urge to vomit)
  5. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  6. Blood sodium decreased
  7. Dehydration (dryness resulting from the removal of water)
  8. Pulmonary oedema (fluid accumulation in the lungs)
  9. Viral infection
  10. Death

What are the existing conditions these people have? *

  1. Cardiac Failure Chronic: 11 people, 37.93%
  2. Pre-Existing Disease: 5 people, 17.24%
  3. Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 5 people, 17.24%
  4. Vasodilatation (widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls): 4 people, 13.79%
  5. Cardiomyopathy (weakening of the heart muscle): 4 people, 13.79%
  6. Platelet Aggregation Inhibition: 4 people, 13.79%
  7. Blood Osmolarity Decreased: 4 people, 13.79%
  8. High Blood Pressure: 4 people, 13.79%
  9. Urination - Excessive Volume: 4 people, 13.79%
  10. Coronary Artery Dilatation: 4 people, 13.79%

* Approximation only. Some reports may have incomplete information.

Do you take Isosorbide mononitrate and Tolvaptan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Isosorbide mononitrate and Tolvaptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Isosorbide mononitrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tolvaptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Isosorbide mononitrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tolvaptan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on isosorbide mononitrate and tolvaptan (the active ingredients of Isosorbide mononitrate and Tolvaptan, respectively), and Isosorbide mononitrate and Tolvaptan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: